GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » NonCurrent Deferred Liabilities

Calidi Biotherapeutics (Calidi Biotherapeutics) NonCurrent Deferred Liabilities : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Calidi Biotherapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

Calidi Biotherapeutics NonCurrent Deferred Liabilities Historical Data

The historical data trend for Calidi Biotherapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics NonCurrent Deferred Liabilities Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
- - - -

Calidi Biotherapeutics Quarterly Data
Dec20 Sep21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Calidi Biotherapeutics NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines